OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
300206$13.7158

Edan Instruments Inc

Advanced Medical Equipment & TechnologyVerified

Edan Instruments Inc maintains a strong liquidity position, with a current ratio of 4.67 and a debt-to-equity ratio of 0.02, indicating minimal leverage and a conservative capital structure. The company's liquidity is further supported by a free cash flow of 157.5 million CNY, which provides flexibility for reinvestment or shareholder returns. However, the risk assessment notes that net cash is negative after subtracting total debt, suggesting potential short-term liquidity constraints. Profitability metrics show that Edan Instruments Inc is performing well relative to industry standards. The company's return on equity (ROE) of 13.94% and return on assets (ROA) of 11.56% are strong indicators of efficient capital use and asset management. Gross profit of 1.16 billion CNY and operating income of 311.6 million CNY reflect solid cost control and pricing power in its core markets. Geographically, the company's revenue is concentrated in its domestic market, with no disclosed international revenue segments. This concentration may expose the company to regulatory and economic risks specific to its home region. The company operates in a single business segment, which simplifies its operations but also limits diversification benefits. Looking ahead, Edan Instruments Inc is projected to maintain a stable growth trajectory. Analysts expect the company to report an EPS of 0.61 CNY, up from the last reported 0.53 CNY, indicating a positive earnings outlook. The company's revenue of 1.999 billion CNY in the latest period suggests a strong foundation for future growth, though the absence of disclosed revenue growth rates makes it difficult to assess acceleration. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's low dilution risk is supported by the absence of dilutive shares and a stable share count. However, the negative net cash position after debt subtraction introduces some uncertainty regarding short-term liquidity. Recent events, including analyst estimates and financial disclosures, indicate a positive sentiment among investors. The company has received a strong-buy recommendation from one analyst, with no hold, buy, or sell ratings, suggesting a favorable outlook. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.

30-day price · 300206+0.66 (+5.1%)
Low$12.90High$15.79Close$13.59As of20 May, 00:00 UTC
Profile
CompanyEdan Instruments Inc
Ticker300206.SZ
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Edan Instruments Inc designs, develops, and sells advanced medical equipment and technology, primarily focused on diagnostic and monitoring devices for healthcare applications.

Classification. Edan Instruments Inc is classified under the Healthcare Services & Equipment business sector and the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.

Edan Instruments Inc maintains a strong liquidity position, with a current ratio of 4.67 and a debt-to-equity ratio of 0.02, indicating minimal leverage and a conservative capital structure. The company's liquidity is further supported by a free cash flow of 157.5 million CNY, which provides flexibility for reinvestment or shareholder returns. However, the risk assessment notes that net cash is negative after subtracting total debt, suggesting potential short-term liquidity constraints. Profitability metrics show that Edan Instruments Inc is performing well relative to industry standards. The company's return on equity (ROE) of 13.94% and return on assets (ROA) of 11.56% are strong indicators of efficient capital use and asset management. Gross profit of 1.16 billion CNY and operating income of 311.6 million CNY reflect solid cost control and pricing power in its core markets. Geographically, the company's revenue is concentrated in its domestic market, with no disclosed international revenue segments. This concentration may expose the company to regulatory and economic risks specific to its home region. The company operates in a single business segment, which simplifies its operations but also limits diversification benefits. Looking ahead, Edan Instruments Inc is projected to maintain a stable growth trajectory. Analysts expect the company to report an EPS of 0.61 CNY, up from the last reported 0.53 CNY, indicating a positive earnings outlook. The company's revenue of 1.999 billion CNY in the latest period suggests a strong foundation for future growth, though the absence of disclosed revenue growth rates makes it difficult to assess acceleration. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's low dilution risk is supported by the absence of dilutive shares and a stable share count. However, the negative net cash position after debt subtraction introduces some uncertainty regarding short-term liquidity. Recent events, including analyst estimates and financial disclosures, indicate a positive sentiment among investors. The company has received a strong-buy recommendation from one analyst, with no hold, buy, or sell ratings, suggesting a favorable outlook. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.
Key takeaways
  • Edan Instruments Inc maintains a strong liquidity position with a current ratio of 4.67 and a low debt-to-equity ratio of 0.02.
  • The company's profitability is robust, with ROE of 13.94% and ROA of 11.56%, indicating efficient capital and asset use.
  • Revenue is concentrated in a single geographic and business segment, which may increase exposure to regional and sector-specific risks.
  • Analysts project a positive earnings outlook, with an expected EPS of 0.61 CNY, up from the last reported 0.53 CNY.
  • The company faces a medium liquidity risk and a low dilution risk, with no dilutive shares outstanding.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$2.00B
Gross profit$1.16B
Operating income$311.6M
Net income$305.6M
R&D
SG&A
D&A
SBC
Operating cash flow$352.9M
CapEx-$84.7M
Free cash flow$157.5M
Total assets$2.64B
Total liabilities$451.0M
Total equity$2.19B
Cash & equivalents
Long-term debt$39.2M
Valuation
Market price$13.71
Market cap$7.95B
Enterprise value$7.99B
P/E26.0
Reported non-GAAP P/E
EV/Revenue4.0
EV/Op income25.6
EV/OCF22.6
P/B3.6
P/Tangible book3.6
Tangible book$2.19B
Net cash-$39.2M
Current ratio4.7
Debt/Equity0.0
ROA11.6%
ROE13.9%
Cash conversion1.1%
CapEx/Revenue-4.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Advanced Medical Equipment & Technology · cohort 3 companies
Metric300206Activity
Op margin15.6%19.4% medp25 17.8% · p75 22.0%bottom quartile
Net margin15.3%17.7% medp25 16.4% · p75 19.0%bottom quartile
Gross margin58.1%73.5% medp25 71.3% · p75 75.8%bottom quartile
R&D / revenue6.2% medp25 4.7% · p75 12.0%
CapEx / revenue-4.2%4.3% medp25 3.9% · p75 4.3%bottom quartile
Debt / equity2.0%41.5% medp25 29.2% · p75 51.3%bottom quartile
Observations
IR observations
Mean recommendation1.00 (1=strong buy, 5=strong sell)
Strong-buy count1.00
Buy count0.00
Hold count0.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate0.61 CNY
Last actual EPS0.53 CNY
Mean revenue estimate2,199,000,000 CNY
Last actual revenue1,998,852,000 CNY
Mean EBIT estimate355,000,000 CNY
Source: analysis-pipeline (hybrid)Generated: 2026-05-21 01:56 UTCJob: 4ebd4417